Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer

Inoue Tetsuya; Katoh Norio; Onimaru Rikiya; Shimizu Shinichi; Tsuchiya Kazuhiko; Suzuki Ryusuke; Sakakibara-Konishi Jun; Shinagawa Naofumi; Oizumi Satoshi; Shirato Hiroki

Title	en Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer
Creator	en Inoue, Tetsuya NRID 1000010431363 en Katoh, Norio NRID 1000080572495 en Onimaru, Rikiya NRID 1000080374461 en Shimizu, Shinichi NRID 1000050463724 en Tsuchiya, Kazuhiko NRID 1000060580892 en Suzuki, Ryusuke NRID 1000000400052 en Sakakibara-Konishi, Jun NRID 1000050374278 en Shinagawa, Naofumi NRID 1000020431372 en Oizumi, Satoshi NRID 1000010421968 en Shirato, Hiroki NRID 1000020187537
Accessrights	open access
Rights	http://creativecommons.org/licenses/by/2.0/ en Creative Commons Attribution 2.0 Generic
Subject	Other en Stereotactic body radiotherapy Other en Radiation pneumonitis Other en Non-small cell lung cancer Other en Real-time tumor-tracking Other en Tumor motion Other en Gated radiotherapy NDC 492
Description	Abstract en Background: To clarify the clinical outcomes of two dose schedule of stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) using a real-time tumor-tracking radiation therapy (RTRT) system in single institution. Methods: Using a superposition algorithm, we administered 48 Gy in 4 fractions at the isocenter in 2005-2006 and 40 Gy in 4 fractions to the 95% volume of PTV in 2007-2010 with a treatment period of 4 to 7 days. Target volume margins were fixed irrespective of the tumor amplitude. Results: In total, 109 patients (79 T1N0M0 and 30 T2N0M0). With a median follow-up period of 25 months (range, 4 to 72 months), the 5-year local control rate (LC) was 78% and the 5-year overall survival rate (OS) was 64%. Grade 2, 3, 4, and 5 radiation pneumonitis (RP) was experienced by 15 (13.8%), 3 (2.8%), 0, and 0 patients, respectively. The mean lung dose (MLD) and the volume of lung receiving 20 Gy (V20) were significantly higher in patients with RP Grade 2/3 than in those with RP Grade 0/1 (MLD p = 0.002, V20 p = 0.003). There was no correlation between larger maximum amplitude of marker movement and larger PTV (r = 0.137), MLD (r = 0.046), or V20 (r = 0.158). Conclusions: SBRT using the RTRT system achieved LC and OS comparable to other SBRT studies with very low incidence of RP, which was consistent with the small MLD and V20 irrespective of tumor amplitude. For stage I NSCLC, SBRT using RTRT was suggested to be reliable and effective, especially for patients with large amplitude of tumor movement.
Publisher	en BIOMED CENTRAL
Date	Issued2013-03-21
Language	eng
Resource Type	journal article
Version Type	VoR
Identifier	HDL http://hdl.handle.net/2115/52757
Relation	isIdenticalTo DOI https://doi.org/10.1186/1748-717X-8-69
Journal	PISSN 1748-717X en Radiation Oncology Volume Number8 Page Start69
File	fulltext 1748-717X-8-69.pdf 370.46 KB (application/pdf) Issued2013-03-21
Oaidate	2023-07-26